Distal 10q trisomy with copy number gain in chromosome region 10q23.1–10q25.1: the Wnt signaling pathway is the most pertinent to the gene content in the region of copy number gain: a case report

BMC Research Notes

Cheng-Da Hsu¹  Yu-Hsin Chen¹  Joseph Hang Leung²  Chung-Nun Chao³  Hsin-Hsu Chou³  Siew-Lee Wong³ 

[1] Departments of Medical Research, Ditmanson Medical Foundation Chia-Yi Christian Hospital, 539 Zhongxiao Road, East District, Chiayi 600, Taiwan;Departments of Radiology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan;Departments of Pediatrics, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan

关键词: PTEN;    NFKB2;    LZTS2;    WNT8B;    Wnt signaling pathway;    KEGG pathway analysis;    GO analysis;    Database for annotation, visualization and integrated discovery (DAVID);    Copy number variation region;    Copy number variation;    Array-comparative genomic hybridization;    Chromosome 10q23.1–10q25.1;    Distal 10q trisomy;   

Others  :  1231718
DOI  :  10.1186/s13104-015-1213-x

 received in 2014-08-01, accepted in 2015-05-27,  发布年份 2015

【 摘 要 】

Background

Complete or partial trisomy 10q involves a duplication of 10q, or the long arm of chromosome 10. Distal 10q trisomy is a well-recognized and defined but rare genetic syndrome in which duplication of distal segments of 10q results in a pattern of malformations. Although abnormal chromosome phenotypes are commonly detected by visualization of chromosomes by traditional cytogenetic techniques, this approach is marginal in both diagnostic sensitivity and potential for biological interpretation, thus making implementation of advanced techniques and analysis methods an important consideration in a health service.

Case presentation

The present study describes the case of a Taiwanese boy from healthy parents with mental, growth, and psychomotor retardations. Additional clinical features included facial dysmorphism, microcephaly, brain atrophy, camptodactyly, and—as the first reported case—bilateral renal atrophy with chronic kidney disease stage 2 and the presence of a renal cyst in one kidney. A novel 21.8 Mb copy number variation region in chromosome region 10q23.1–10q25.1 was verified by array-comparative genomic hybridization in combination with quantitative real-time polymerase chain reaction. Subsequently, 200 protein-coding genes were identified in this copy number variation region and analyzed for their biological meaning using the database for annotation, visualization and integrated discovery.

Conclusion

According to the result of gene functional enrichment analysis using database for annotation, visualization and integrated discovery, the Wnt signaling pathway is the most pertinent to the gene content in the copy number variation region. A change in the expression levels of some Wnt signaling pathway components and of NFKB2 and PTEN genes due to a gain in their gene copy number may be associated with the patient’s clinical outcomes including brain atrophy, bilateral renal atrophy with chronic kidney disease stage 2, a renal cyst in one kidney, and growth retardation.

【 授权许可】

   
2015 Wong et al.

【 图 表 】

Figure1.

Figure2.

Figure3.

Figure1.

Figure2.

Figure3.

【 参考文献 】

• [1]de Grouchy J, Canet J: 6-12 13-15 translocation and partial 6-12 trisomy (probably 10). Ann Genet 1965, 8(1):16-20.
• [2]Davies J, Jaffe A, Bush A: Distal 10q trisomy syndrome with unusual cardiac and pulmonary abnormalities. J Med Genet 1998, 35(1):72-74.
• [3]Ahn JW, Bint S, Bergbaum A, Mann K, Hall RP, Ogilvie CM: Array CGH as a first line diagnostic test in place of karyotyping for postnatal referrals—results from 4 years’ clinical application for over 8,700 patients. Mol Cytogenet 2013, 6(1):16. BioMed Central Full Text
• [4]Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408.
• [5]Bodin L, Beaune PH, Loriot MA: Determination of cytochrome P450 2D6 (CYP2D6) gene copy number by real-time quantitative PCR. J Biomed Biotechnol 2005, 2005(3):248-253.
• [6]da Huang W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4(1):44-57.
• [7]Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al.: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000, 25(1):25-29.
• [8]Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M: KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 2010, 38(Database issue):D355-D360.
• [9]Zhao L, Hayes K, Khan Z, Glassman A: Spectral karyotyping study of chromosome abnormalities in human leukemia. Cancer Genet Cytogenet 2001, 127(2):143-147.
• [10]Poddighe PJ, Moesker O, Smeets D, Awwad BH, Ramaekers FC, Hopman AH: Interphase cytogenetics of hematological cancer: comparison of classical karyotyping and in situ hybridization using a panel of eleven chromosome specific DNA probes. Cancer Res 1991, 51(7):1959-1967.
• [11]Pan M, Li FT, Li Y, Jiang FM, Li DZ, Lau TK, et al.: Discordant results between fetal karyotyping and non-invasive prenatal testing by maternal plasma sequencing in a case of uniparental disomy 21 due to trisomic rescue. Prenat Diagn 2013, 33(6):598-601.
• [12]Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al.: Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010, 86(5):749-764.
• [13]Park SJ, Jung EH, Ryu RS, Kang HW, Ko JM, Kim HJ, et al.: Clinical implementation of whole-genome array CGH as a first-tier test in 5080 pre and postnatal cases. Mol Cytogenet 2011, 4:12. BioMed Central Full Text
• [14]Salman M, Jhanwar SC, Ostrer H: Will the new cytogenetics replace the old cytogenetics? Clin Genet 2004, 66(4):265-275.
• [15]Nowakowska BA, de Leeuw N, Ruivenkamp CA, Sikkema-Raddatz B, Crolla JA, Thoelen R, et al.: Parental insertional balanced translocations are an important cause of apparently de novo CNVs in patients with developmental anomalies. Eur J Human Genet EJHG 2012, 20(2):166-170.
• [16]Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 2006, 127(3):469-480.
• [17]Lako M, Lindsay S, Bullen P, Wilson DI, Robson SC, Strachan T: A novel mammalian wnt gene, WNT8B, shows brain-restricted expression in early development, with sharply delimited expression boundaries in the developing forebrain. Hum Mol Genet 1998, 7(5):813-822.
• [18]Pulkkinen K, Murugan S, Vainio S: Wnt signaling in kidney development and disease. Organogenesis 2008, 4(2):55-59.
• [19]Saadi-Kheddouci S, Berrebi D, Romagnolo B, Cluzeaud F, Peuchmaur M, Kahn A, et al.: Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene. Oncogene 2001, 20(42):5972-5981.
• [20]Shiina H, Igawa M, Breault J, Ribeiro-Filho L, Pookot D, Urakami S, et al.: The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res 2003, 9(6):2121-2132.
• [21]Li CM, Kim CE, Margolin AA, Guo M, Zhu J, Mason JM, et al.: CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms’ tumors. Am J Pathol 2004, 165(6):1943-1953.
• [22]Surendran K, Schiavi S, Hruska KA: Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol JASN 2005, 16(8):2373-2384.
• [23]Haumaitre C, Fabre M, Cormier S, Baumann C, Delezoide AL, Cereghini S: Severe pancreas hypoplasia and multicystic renal dysplasia in two human fetuses carrying novel HNF1beta/MODY5 mutations. Hum Mol Genet 2006, 15(15):2363-2375.
• [24]Terada Y, Tanaka H, Okado T, Shimamura H, Inoshita S, Kuwahara M, et al.: Expression and function of the developmental gene Wnt-4 during experimental acute renal failure in rats. J Am Soc Nephrol JASN 2003, 14(5):1223-1233.
• [25]Carl M, Bianco IH, Bajoghli B, Aghaallaei N, Czerny T, Wilson SW: Wnt/Axin1/beta-catenin signaling regulates asymmetric nodal activation, elaboration, and concordance of CNS asymmetries. Neuron 2007, 55(3):393-405.
• [26]Peng Y, Clark C, Luong R, Tu WH, Lee J, Johnson DT, et al.: The leucine zipper putative tumor suppressor 2 protein LZTS2 regulates kidney development. J Biol Chem 2011, 286(46):40331-40342.
• [27]Maehama T, Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998, 273(22):13375-13378.
• [28]Fruman DA, Meyers RE, Cantley LC: Phosphoinositide kinases. Annu Rev Biochem 1998, 67:481-507.
• [29]Chen CP, Chen YJ, Tsai FJ, Chern SR, Wang W: NFkappaB2 gene duplication is associated with fetal pyelectasis in partial trisomy 10q (10q24.1– > qter). Prenat Diagn 2008, 28(4):364-365.
• [30]Ismaili K, Avni FE, Wissing KM, Hall M: Brussels Free University Perinatal Nephrology Study G: Long-term clinical outcome of infants with mild and moderate fetal pyelectasis: validation of neonatal ultrasound as a screening tool to detect significant nephrouropathies. J Pediatr 2004, 144(6):759-765.